Marty
Well-known member
I e-mailed Dr.Puskas ,chief of heart surgery at Emory, asking him how the trial was going (trying to find out if On-x valvers need to take warfarin) and also what he thought of the On-x compared to St. Jude and Medtronics.
Here is the answer:
Dear Dr Thomas:
I do feel that the On-X valve is superior in design and materials to any of the
previous valves. It was just being introduced to the market 10 years ago when
you had your MVR. (I should mention that I have NO financial relationship to the
valve manufacturer.)
The results of the PROACT trial will not be available for at least 6 years. We
have enrolled over 400 patients, surpassing 1/3 of the planned 1200 patient
enrollment. All will be followed for 5 years.
Results to date are too limited in follow-up to make any recommendation other
than the standard coumadin and baby aspirin that is recommended in the present
ACC/AHA guidelines for anticoagulation of mechanical prostheses.
I can state that the independent Data Safety and Monitoring Board of the PROACT
trial has met regularly to review adverse events in the control and "test"
groups of the Trial. The DSMB is empowered to halt the trial at any time if it
feels that continuing the trial would jeopardize patient safety. It has not
found any reason to contemplate such an action.
Warm regards,
John Puskas
Here is the answer:
Dear Dr Thomas:
I do feel that the On-X valve is superior in design and materials to any of the
previous valves. It was just being introduced to the market 10 years ago when
you had your MVR. (I should mention that I have NO financial relationship to the
valve manufacturer.)
The results of the PROACT trial will not be available for at least 6 years. We
have enrolled over 400 patients, surpassing 1/3 of the planned 1200 patient
enrollment. All will be followed for 5 years.
Results to date are too limited in follow-up to make any recommendation other
than the standard coumadin and baby aspirin that is recommended in the present
ACC/AHA guidelines for anticoagulation of mechanical prostheses.
I can state that the independent Data Safety and Monitoring Board of the PROACT
trial has met regularly to review adverse events in the control and "test"
groups of the Trial. The DSMB is empowered to halt the trial at any time if it
feels that continuing the trial would jeopardize patient safety. It has not
found any reason to contemplate such an action.
Warm regards,
John Puskas